All News

bathroom scale

The Influence of Obesity on Choice of Biologic in Rheumatoid Arthritis

Richard Conway, MBBChBAO, PhD

In rheumatoid arthritis we have a wide range of options available to us when we progress to a biologic treatment option. We have little to differentiate between these agents based on the clinical trials.

Read Article
RheumNow Podcast square

RheumNow Podcast - Unwillingness to Change Therapy (11.19.21)

Jack Cush, MD

Surely you’ve seen this or been plagued by this patient, one that is not doing well, in need of a new regimen; you outline it, timeline it, define the side effects and send them off with a new prescription..

Read Article
Giant-Cell_Vasculitis.jpg

Top vasculitis takeaways from ACR 2021

Janet Pope, MD, MPH, FRCPC

There were several hot topics at ACR21. Here I concentrate on top abstracts in vasculitis. 

Read Article
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Jack Cush, MD

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
heel enthesitis spur calcaneal

Predicting RA, and Treatment of Subclinical Arthritis

Meral K. El Ramahi, MD, FACP, FACR

Identifying patients that will develop RA in situations of seropositivity without overt clinical arthritis or identifying patients with undifferentiated oligo/polyarthritis that will develop RA remains a challenge in the field of rheumatology. 

Read Article
iv.infusion.jpg

Can "Ultra-low" dose Rituximab work for RA?

Eric Dein, MD

The REDO trial presented data in abstract 1443 in an oral presentation challenging how low we can go with rituximab for rheumatoid arthritis. Their study randomized 118 patients with rheumatoid arthritis to 1000 mg, 500 mg, and "ultra-low" dose 200 mg.

Read Article
Potpourri of Biosimilar Trials: Dr. Jonathan Kay discusses a number of biosimilar trials presented at the #ACR21 annual meeting, including abstracts #0822, #0820, #0817 and #0823. https://t.co/aQXrKKZXhb https://t.co/4Bn7rvogHY

Links:

Dr. John Cush RheumNow ( View Tweet)
Does Obesity Play a Role in Biologic Response? Dr. Eric Dein ( @ejdein1) discusses abstract #0588 presented at the #ACR21 annual meeting. https://t.co/yJNOFv3KOC https://t.co/KvBrFlXLfW

Links:

Dr. John Cush RheumNow ( View Tweet)
Factors Associated with Poor Vaccine Response in Rituximab: Dr. Yuzaiful Yusof (@Yuz6Yusof) discusses abstract #0437 presented at the #ACR21 annual meeting. https://t.co/T0PFiZlbTa https://t.co/idj5T7j7ke

Links:

Dr. John Cush RheumNow ( View Tweet)
Comparative risks of skin SCC and BCC with different DMARDs. Abatacept appeared worst, HR 2.18, but may be residual confounding due to burden disease/comorbidities. Abstr#1942 #ACR21 @RheumNow https://t.co/UzOwuKKFmX
Richard Conway RichardPAConway ( View Tweet)
Who declines most with #scleroderma #ILD - early dcSSc, ⬆️CRP, ⬆️mRSS all w more ⤵️FVC. Results verified in SENSIS trial of SSc ILD where #nintedanib was superior to placebo abst#1846 #ACR21 @RheumNow https://t.co/eckUj0qwch
Janet Pope Janetbirdope ( View Tweet)
Should we be measuring drug levels in pts taking infliximab? ⭐️Drug monitoring vs. standard dosing showed 73% sustained control vs. 55% (RA, PsA, SpA, UC, Crohn's, PsO) #ACR21 Abs#1946 #ACRBest @RheumNow https://t.co/sWMen50ljP https://t.co/F4Wpqis3id

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
OK is this a swan or a swan song? Graph looks like a swan 🦢 but message is NO #MACE differences in PsA on csDMARDs v #biologics #ACR21 abst#1833 @RheumNow https://t.co/TM91z5wiFY

Links:

Janet Pope Janetbirdope ( View Tweet)

So are we in an era of #monotherapy with bDMARDs in #PsA? Ustekinumab & Secukinumab not different w or without #MTX. Abst#L12 @RheumNow #ACR21 https://t.co/Zp5owTpLvm

Links:

Janet Pope Janetbirdope ( View Tweet)

Important late breaker @TerrierBen, DBRCT of RTX vs GC (FFS=0) or CYC (FFS>0) for EGPA RTX not superior to CYC (64% RTX vs 60% CYC BVAS remission d180, p = 0.745); similar in subgroups Feel like this lends support to (~surprising) ACR/VF recs for EGPA? #ACR21 #ACRAmbassador https://t.co/gpsPtXF6pj
Mike Putman EBRheum ( View Tweet)
#ACR21 L19: TitAIN: Secukinumab for GCA ⭐️Phase 2 study with n=52 ⭐️70% of SEC sustained remission at wk 28 vs 20% PBO, 59% at week 52 vs 8% ⬇️Cumulative prednisolone through wk 52 (2.8g v 3.4g) - Looking forward to larger study @Rheumnow https://t.co/cuM9LcEr4u https://t.co/TmyS0kixFg

Links:

Eric Dein ericdeinmd ( View Tweet)
#ACR21 L21. REOVAS: RTX for EGPA ⭐️CYC traditionally preferred for 5-factor score>0 ▶️Remission rates and relapse-free survival comparable bw RTX and conventional. RTX not superior for induction ▶️No diff in ANCA+/-, naive v relapse, FFS https://t.co/cuM9LcEr4u @Rheumnow

Links:

Eric Dein ericdeinmd ( View Tweet)

Racial disparities & Co-morbidities in PsA findings. Amongst important others, increased biologic use in Caucasians w/ PsA vs DMARDs in black PsA pts. View Abs 1780 for other relevant findings. #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/0uKsa8i0bG https://t.co/R9YkxYqXws

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
RHEKISS registry: SpA pts on bDMARDs at conception are NOT at inc. risk for adverse pregnancy outcomes. Discontinuation of bDMARDs after conception is assoc'd w/ inc. dz activity during/after pregnancy & flare risk. Abs 1730 #ACR21 #RheumNow @RheumNow https://t.co/b2wI9GZios https://t.co/wsuvv3hF0v

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
b/tsDMARDs + tumor response in rheum irAEs Excellent point by @CCalabreseDO @LCalabreseDO: - despite progression in 5/10, DMARD contribution uncertain (bad cancer) - without DMARD, ICI would have had to stop crucial question, prospective study needed #ACR21 ABST1519 @RheumNow https://t.co/omJnTNVscH
David Liew drdavidliew ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×